AtriCure announced the first patient treatment with its AtriClip FLEX-Mini device for left atrial appendage (LAA) management.
The device, which recently received 510(k) clearance from the US Food and Drug Administration (FDA), is claimed to be the smallest profile surgical LAA device in the market.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The AtriClip FLEX-Mini device is designed to provide surgeons with enhanced access and increased visibility during procedures.
This device builds upon the proven technology of the AtriClip platform, which is known for its ease of use and design simplicity.
AtriCure CEO and president Michael Carrel said: “The AtriClip FLEX-Mini is an unparalleled product that reinforces our position as the market leader in surgical LAA management.
“With nearly 600,000 AtriClip devices sold globally, we are having a significant impact on patients’ lives. Continuing to innovate and enhance the unique features of our AtriClip platform will support even greater growth in this market.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe AtriClip FLEX-Mini device features a fully enclosed design with parallel beams that apply constant closing force, thereby ensuring optimal pressure on the atrial tissue.
Its low-profile design does not compromise stability, allowing for better control during surgeries. The ergonomic handle of the device is designed for single-handed placement, making the application process more straightforward for physicians.
In April 2024, AtriCure launched the cryoSPHERE+ cryoablation probe device to improve post-operative pain management.
The cryoSPHERE+ probe, which is part of the cryoICE platform, features advanced insulation technology that reduces freeze times by 25% compared to the legacy cryoSPHERE device.
